Safety of Vonoprazan-Amoxicillin Dual Therapy Versus Concomitant Quadruple Therapy for H. Pylori Eradication
Key facts
- Who runs it
- Ignacio Moratorio
- Where
- Uruguay4 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 100 people, planned
- Started
- 5 Aug 2026
- Expected to end
- 1 Apr 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Vonoprazan (Reference)
- Amoxicillin
- Metronidazole
- Clarithromycin 500 mg
- Omeprazole
- Record updated
- 9 November 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Adults aged 18 to 75 years attending one of the four participating tertiary-care centres
- Helicobacter pylori infection confirmed by at least one of the following: gastric histology, endoscopic rapid urease test, stool antigen test, serology, or urea breath test
- Indication for eradication therapy according to the Maastricht VI/Florence consensus
- Written informed consent
Who cannot take part
- Previous Helicobacter pylori eradication treatment
- Antibiotic use within the month before enrolment
- Previous gastric resection
- * Known allergy or hypersensitivity to any of the study drugs (vonoprazan, amoxicillin, omeprazole, clarithromycin or metronidazole)
- Use of histamine H2-receptor antagonists, proton pump inhibitors or potassium-competitive acid blockers within the two weeks before enrolment
- Pregnancy
- Unwillingness to participate
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
This trial is currently available in Uruguay.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Problem. Helicobacter pylori infection is the most prevalent bacterial infection in humans and the main modifiable risk factor for gastric adenocarcinoma. In Uruguay, where clarithromycin resistance is either unknown or above 15% and neither bismuth nor tetracyclines are available, the first-line regimen is non-bismuth quadruple (concomitant) therapy with omeprazole, clarithromycin, amoxicillin and metronidazole (OCAM) for 14 days. Its main limitation is tolerability: adverse events affect up to 40% of patients and account for discontinuation rates of 2-10%, and the regimen exerts selective pressure through four simultaneous drugs.
Read full original descriptionShow less
Research question. In adult patients with H. pylori infection and an indication for eradication treated at tertiary care centers in Uruguay, does dual therapy with vonoprazan and amoxicillin for 14 days reduce the frequency and severity of adverse events compared with non-bismuth concomitant quadruple therapy (OCAM) for 14 days? Primary objective. To compare the frequency and severity of adverse events between both eradication regimens.
Design. Randomized, experimental, prospective, multicenter (4 centers), triple-blinded clinical trial (treating physician, research team and statistician). Reported in accordance with the CONSORT statement.
Population. Patients aged 18 to 75 years with H. pylori infection confirmed by histology, rapid urease test, stool antigen test, serology or urea breath test, with an indication for eradication according to the Maastricht VI/Florence consensus, treated at Hospital de Clínicas, Asistencial Médica-Sanatorio Cantegril, DNSP and COMEPA.
Intervention. Group A: vonoprazan 20 mg every 12 hours plus amoxicillin 1 g every 8 hours for 14 days. Group B: omeprazole 20 mg, clarithromycin 500 mg, metronidazole 500 mg and amoxicillin 1 g, all every 12 hours for 14 days.
Primary endpoint. Maximum adverse event severity per participant, an ordinal variable with four categories (absent, mild, moderate, severe) according to CTCAE v5.0, collected through a self-administered questionnaire at the end of treatment.
Secondary endpoints. Eradication rate, confirmed at least 45 days after treatment initiation; treatment adherence (intake of ≥80% of the prescribed regimen); number of distinct symptoms and duration in days per participant.
Sample size and analysis. Fifty participants per group. Bivariate comparisons were performed with the chi-square test or Fisher exact test, and ordinal logistic regression was applied with assessment of the proportional odds assumption (Brant test), in Stata 18.0.
Keywords: Helicobacter pylori; Vonoprazan; Amoxicillin; Dual therapy; Drug-Related Side Effects and Adverse Reactions; Randomized Controlled Trial; Uruguay.
The 2 groups in the trial
- Dual therapy: vonoprazan + amoxicillinTreatment being tested
H. pylori treatment consisting of vonoprazan and amoxycilline
Treatment: Vonoprazan (Reference) and Amoxicillin
- Quadruple therapy: omeprazole + clarithromycin + amoxicillin + metronidazole (OCAM)Existing treatment, for comparison
H. pylori treatment consisting of omeprazole, amoxycilline, clarithromicine, methronidazole
Treatment: Amoxicillin, Metronidazole, Clarithromycin 500 mg, and Omeprazole
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Safety of Dual Therapy With Vonoprazan and Amoxicillin Versus Non-Bismuth Concomitant Quadruple Therapy With Omeprazole, Clarithromycin, Amoxicillin and Metronidazole for Helicobacter Pylori Eradication: A Randomized Clinical Trial
- Criteria questions
- Built from NCT07924098, who can take part
- Record updated
- 9 November 2026